- Home
- DBD vs IRON Comparison
DBD vs IRON Comparison
Compare DBD & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- IRON
- Stock Information
- Founded
- DBD 1859
- IRON 2017
- Country
- DBD United States
- IRON United States
- Employees
- DBD N/A
- IRON N/A
- Industry
- DBD EDP Services
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- IRON Health Care
- Exchange
- DBD Nasdaq
- IRON Nasdaq
- Market Cap
- DBD 1.6B
- IRON 1.9B
- IPO Year
- DBD N/A
- IRON N/A
- Fundamental
- Price
- DBD $44.51
- IRON $58.25
- Analyst Decision
- DBD Strong Buy
- IRON Strong Buy
- Analyst Count
- DBD 2
- IRON 10
- Target Price
- DBD $57.50
- IRON $73.70
- AVG Volume (30 Days)
- DBD 103.8K
- IRON 267.1K
- Earning Date
- DBD 02-12-2025
- IRON 11-12-2024
- Dividend Yield
- DBD N/A
- IRON N/A
- EPS Growth
- DBD N/A
- IRON N/A
- EPS
- DBD 0.00
- IRON N/A
- Revenue
- DBD $3,799,000,000.00
- IRON N/A
- Revenue This Year
- DBD $0.73
- IRON N/A
- Revenue Next Year
- DBD $1.58
- IRON N/A
- P/E Ratio
- DBD $8,356.71
- IRON N/A
- Revenue Growth
- DBD 2.88
- IRON N/A
- 52 Week Low
- DBD $29.63
- IRON $25.60
- 52 Week High
- DBD $51.81
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- DBD 55.38
- IRON 40.61
- Support Level
- DBD $39.90
- IRON $57.09
- Resistance Level
- DBD $43.46
- IRON $61.08
- Average True Range (ATR)
- DBD 1.01
- IRON 2.83
- MACD
- DBD 0.19
- IRON -0.58
- Stochastic Oscillator
- DBD 94.86
- IRON 14.04
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are banking which offers integrated solutions for financial institutions and retail which offers solutions, software, and services which improve the checkout process for retailers.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.